Loading cancer entity…
Loading cancer entity…
Clinical trials
98 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 7 | Mayo ClinicOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | terminated | Phase 1 | 85 | Halozyme TherapeuticsINDUSTRY | 3 |
| Feb 7, 2020 |
| clinicaltrials |
| NCT00630890 | Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) | terminated | Phase 1 | 11 | University of California, San FranciscoOTHER | 1 | Sep 11, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 22, 2025source: clinicaltrials